AstraZeneca Results Presentation Deck

Breast cancer: well-positioned with at least five medicines Potential to cover most patients across settings and lines of treatment HER2+ c.20% of patients Hormone- receptor positive (HR+) c.65% of patients Triple-negative (TNBC) c.15% of patients Illustrative; includes trials planned. 33 Early/curative setting Neo-adjuvant Enhertu monotherapy and potential combos HER low c.55% of patients that are not HER2+ Adjuvant ADC² +/- 10³ camizestrant capivasertib Lynparza (BRCAm) ADC after neo-adjuvant 1st line camizestrant capivasertib combinations ADC +/- 10 capivasertib + CTX4 Metastatic setting 2nd line Enhertu monotherapy and potential combos camizestrant capivasertib combinations Enhertu Lynparza (BRCAm) datopotamab 3rd line Enhertu Enhertu datopotamab deruxtecan 3rd line+ datopotamab deruxtecan 1. HER2-low prevalence is anticipated to be c.35-40% in TNBC 2. Antibody drug conjugates (Enhertu and datopo- tamab deruxtecan) 3. Immunotherapy 4. Chemotherapy. 3

View entire presentation